公开(公告)号：US08629150B2

公开(公告)日：2014-01-14

申请号：US13625186

申请日：2012-09-24

Applicant: Bristol-Myers Squibb Company

Inventor： Tao Wang ,  Li-Qiang Sun ,  Paul Michael Scola ,  Zhongxing Zhang ,  Qian Zhao

IPC: C07D498/10 ,  C07D498/18 ,  A61K31/529 ,  A61P31/22

CPC classification number: C07D498/06

Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 本公开提供式I化合物，包括药学上可接受的盐，以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：US20130253196A1

公开(公告)日：2013-09-26

申请号：US13861804

申请日：2013-04-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yasutsugu Ueda ,  Timothy P. Connolly ,  John F. Kadow ,  Nicholas A. Meanwell ,  Tao Wang ,  Chung-Pin H. Chen ,  Kap-Sun Yeung ,  Zhongxing Zhang ,  David Kenneth Leahy ,  Shawn K. Pack ,  Nachimuthu Soundararajan ,  Pierre Sirard ,  Kathia Levesque ,  Dominique Thoraval

IPC: C07F9/6561

CPC classification number: A61K31/675 ,  A61K31/497 ,  A61K45/06 ,  C07D471/04 ,  C07F9/062 ,  C07F9/5728 ,  C07F9/65515 ,  C07F9/65586 ,  C07F9/6561

Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

公开(公告)号：US20180099953A1

公开(公告)日：2018-04-12

申请号：US15551012

申请日：2016-02-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  John F. Kadow

IPC: C07D405/10 ,  A61P31/14 ,  C07D405/12 ,  C07D307/84 ,  C07D413/14 ,  C07D405/14 ,  C07D417/14

CPC classification number: C07D405/10 ,  A61P31/14 ,  C07D307/84 ,  C07D401/10 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and areuseful in treating those infected with HCV.

公开(公告)号：US20180057455A1

公开(公告)日：2018-03-01

申请号：US15689115

申请日：2017-08-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： KAP-SUN YEUNG ,  Katharine A. Grant-Young ,  Juliang Zhu ,  Mark G. Saulnier ,  David B. Frennesson ,  David R. Langley ,  Piyasena Hewawasam ,  Tao Wang ,  Zhongxing Zhang ,  Zhaoxing Meng ,  Li-Qiang Sun ,  Eric Mull ,  Paul Michael Scola

IPC: C07D207/12 ,  C07D211/66 ,  C07D207/16 ,  C07D403/12 ,  C07D401/12 ,  C07D207/14 ,  C07D211/22 ,  C07D213/38 ,  C07D401/14 ,  C07C237/06 ,  C07D295/088 ,  C07D205/04 ,  C07D213/85 ,  C07C217/18 ,  C07D213/73 ,  C07D405/12 ,  C07C255/24 ,  C07D413/14 ,  C07D405/14 ,  C07D213/79 ,  C07D231/12 ,  C07D239/26 ,  C07D277/28 ,  C07D211/90

CPC classification number: C07D207/12 ,  C07C217/18 ,  C07C217/28 ,  C07C217/58 ,  C07C229/14 ,  C07C235/08 ,  C07C237/04 ,  C07C237/06 ,  C07C255/24 ,  C07C255/25 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07D205/04 ,  C07D207/14 ,  C07D207/16 ,  C07D211/22 ,  C07D211/46 ,  C07D211/58 ,  C07D211/60 ,  C07D211/66 ,  C07D211/90 ,  C07D213/38 ,  C07D213/42 ,  C07D213/55 ,  C07D213/73 ,  C07D213/79 ,  C07D213/85 ,  C07D231/12 ,  C07D239/26 ,  C07D277/28 ,  C07D295/088 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/12

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

公开(公告)号：US20180030017A1

公开(公告)日：2018-02-01

申请号：US15551009

申请日：2016-02-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  John F. Kadow

IPC: C07D307/82 ,  C07D405/12

CPC classification number: C07D307/82 ,  C07D307/84 ,  C07D405/12

Abstract: Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

公开(公告)号：US09840511B2

公开(公告)日：2017-12-12

申请号：US15312022

申请日：2015-05-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D307/78 ,  C07D491/048 ,  C07D405/10 ,  C07D307/84

CPC classification number: C07D491/048 ,  C07D307/84 ,  C07D405/10

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: formula (I).

公开(公告)号：US09745322B2

公开(公告)日：2017-08-29

申请号：US14771827

申请日：2014-03-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  Paul Michael Scola

IPC: C07D498/08 ,  A61K31/53 ,  A61P31/14 ,  A61K45/06

CPC classification number: C07D498/08 ,  A61K31/53 ,  A61K45/06

Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US09655902B2

公开(公告)日：2017-05-23

申请号：US14762542

申请日：2014-01-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Ying Han ,  Zhiwei Yin ,  Paul Michael Scola

IPC: C07D251/52 ,  C07D403/14 ,  C07D403/12 ,  A61K31/53 ,  A61P31/14 ,  A61K31/551 ,  A61K45/06

CPC classification number: A61K31/53 ,  A61K31/551 ,  A61K45/06 ,  C07D251/52 ,  C07D403/12 ,  C07D403/14

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US09624245B2

公开(公告)日：2017-04-18

申请号：US14765910

申请日：2014-02-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Zhiwei Yin ,  Li-Qiang Sun ,  Eric Mull ,  Qian Zhao ,  Paul Michael Scola

IPC: C07D519/00 ,  C07D498/22 ,  C07D498/08 ,  C07D498/18 ,  A61K31/53 ,  A61K31/551 ,  A61K45/06 ,  C07D498/20

CPC classification number: C07D498/22 ,  A61K31/53 ,  A61K31/551 ,  A61K45/06 ,  C07D498/08 ,  C07D498/18 ,  C07D498/20

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US09624180B2

公开(公告)日：2017-04-18

申请号：US14762554

申请日：2014-01-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Paul Michael Scola

IPC: C07D251/52 ,  A61K31/53 ,  C07D403/12 ,  A61P31/14 ,  A61K45/06

CPC classification number: C07D251/52 ,  A61K31/53 ,  A61K45/06 ,  C07D403/12

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.